• MiR-3180 Suppresses HCC via Dual Inhibition of SCD1 and CD36

  2026-05-07

  Hong et al. (2023) reveal that miR-3180 acts as a potent inhibitor of hepatocellular carcinoma (HCC) progression by targeting both fatty acid synthesis and uptake pathways through SCD1 and CD36. This dual mechanism highlights miR-3180 as a promising prognostic biomarker and therapeutic target for lipid metabolism-driven cancers.

• Reliable RNA Synthesis for Cell Assays: HyperScribe™ T7 Kit

  2026-05-06

  This article provides scenario-driven, evidence-based guidance for biomedical researchers seeking robust, high-yield in vitro transcription workflows. Using SKU K1047, the HyperScribe™ T7 High Yield RNA Synthesis Kit, we address common lab challenges in RNA production for cell viability, proliferation, and cytotoxicity assays. Protocol recommendations are grounded in quantitative data and direct product specifications.

• Novobiocin Sodium: Advanced Applications in Eukaryotic Patho

  2026-05-06

  Explore the unique role of Novobiocin Sodium, an aminocoumarin antibiotic, in eukaryotic pathogen and cell signaling research. This article introduces new insights and advanced protocols for metabolic enzyme studies and anti-parasitic assays, expanding beyond traditional bacterial applications.

• Z-VEID-FMK: Precision Caspase-6 Inhibition in Neuroinflammat

  2026-05-05

  Explore how Z-VEID-FMK, a potent caspase-6 inhibitor, enables advanced dissection of neuroinflammatory pain pathways and apoptotic mechanisms. This article delivers original insights into protocol optimization and translational assay design, grounded in recent preclinical research.

• A-769662 and AMPK: Rethinking Energy Stress, Autophagy & Met

  2026-05-05

  Explore how A-769662, a potent AMPK activator, is reshaping our understanding of energy metabolism and autophagy regulation. This in-depth analysis integrates recent paradigm-shifting findings to guide advanced metabolic research and protocol optimization.

• SMYD2 Inhibition Mitigates Renal Fibrosis in Cisplatin-Induc

  2026-05-04

  This study demonstrates that pharmacological inhibition of SMYD2, including with LLY-507, significantly reduces renal fibrosis and inflammation in mouse models of cisplatin-induced chronic kidney disease. The findings highlight the central role of SMYD2 in fibrogenesis and suggest its inhibition as a promising epigenetic approach for kidney fibrosis intervention.

• Cinoxacin in Urinary Tract Infection: Mechanisms and Efficac

  2026-05-04

  This article analyzes the mechanistic and clinical findings from Scavone et al. (1982) on Cinoxacin, a quinolone antibiotic targeting bacterial DNA synthesis in Gram-negative urinary pathogens. The study’s innovations in pharmacokinetics and antimicrobial spectrum are contextualized for translational research, with evidence-based discussion of efficacy, resistance, and laboratory protocols.

• Optimizing Reactive Oxygen Species Assay Kit Workflows with

  2026-05-03

  The APExBIO Reactive Oxygen Species Assay Kit empowers researchers with robust, quantitative measurement of oxidative stress using the DCFH-DA fluorescent probe. This article delivers advanced protocol optimizations, practical troubleshooting, and translational insights from recent COPD research—accelerating progress across cell signaling, apoptosis, and disease modeling.

• E-4031 as a hERG Potassium Channel Blocker in Cardiac Resear

  2026-05-02

  E-4031 is a gold-standard hERG potassium channel blocker for modeling cardiac electrophysiological phenomena such as QT interval prolongation and proarrhythmic substrate assessment. This article provides a detailed, experiment-focused guide to leveraging E-4031 in advanced cardiac workflows, with actionable protocol parameters and troubleshooting insights for reproducible, high-content results.

• Cytoskeleton-Dependent Autophagy Triggered by Mechanical Str

  2026-05-02

  This study presents direct experimental evidence that mechanical stress-induced autophagy in human cells depends critically on cytoskeletal microfilaments, with microtubules playing a supporting role. The findings clarify the mechanotransduction pathways underlying cellular adaptation to physical forces and offer new opportunities for investigating cytoskeleton–autophagy interplay in disease models.

• Escitalopram (Lexapro): Optimized Workflows for Antidepressa

  2026-05-01

  Leverage high-purity Escitalopram from APExBIO to drive reproducible antidepressant and anxiolytic studies. This guide details evidence-backed workflows, troubleshooting strategies, and protocol optimization for advanced serotonergic research.

• Angiotensin Peptides Modulate SARS-CoV-2 Spike–Host Binding

  2026-04-30

  Oliveira et al. (2025) demonstrate that naturally occurring angiotensin peptides, including N-terminally truncated forms like Angiotensin III, significantly enhance the binding of SARS-CoV-2 spike protein to host cell receptors, particularly AXL. These findings suggest mechanistic links between the renin–angiotensin system and viral pathogenesis, opening new avenues for research on peptide-mediated modulation of infection.

• NLRP10 Regulates Keratinocyte Survival and Barrier Function

  2026-04-30

  This study identifies NLRP10 as a crucial regulator of epidermal homeostasis in atopic dermatitis, linking its downregulation to impaired keratinocyte survival and differentiation. The mechanistic insights provided highlight NLRP10 as a promising therapeutic target for restoring skin barrier integrity.

• CA-074: Unlocking Cathepsin B’s Role in Necroptosis and Beyo

  2026-04-29

  This thought-leadership article explores the mechanistic and strategic value of CA-074, a selective cathepsin B inhibitor, in dissecting disease pathways such as necroptosis, cancer metastasis, and immune modulation. We connect foundational discoveries—like MLKL-driven lysosomal membrane permeabilization—with translational opportunities, providing actionable guidance for researchers seeking both mechanistic clarity and clinical relevance. Through careful evidence integration, protocol recommendations, and a candid assessment of the competitive landscape, we position APExBIO’s CA-074 as an indispensable tool beyond standard product resources.

• Benzyl Alcohol Mitigates Angiotensin II-Induced Vascular Inj

  2026-04-29

  A recent study identifies benzyl alcohol as a metabolite capable of attenuating vascular and renal damage caused by Angiotensin II in a murine hypertension model. This work provides new evidence for targeting metabolic pathways in pediatric hypertension and vascular smooth muscle cell hypertrophy research.

491 records 15/33 page Previous Next First page 上5页 1112131415 下5页 Last page